HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

The BIG 1-98 trial was financed by Novartis and coordinated by the IBCSG [clinicaltrials.gov IDs = NCT00004205], including the design of the trial, data management, medical review, pathology review, and statistical support. The ATAC Trial was funded by AstraZeneca [clinicaltrials.gov IDs = NCT00849030] and Cancer Research UK. The TEAM trial was funded by Pharmacia/Pfizer [clinicaltrials.gov IDs = NCT00279448] and aspects of the biomarker work was funded by Cancer Research UK. John Bartlett was supported by funding from OICR which is provided through the Ontario Ministry of Research, Innovation and Science